Therapeutic targeting of signaling pathways related to acute myeloid and chronic lymphocytic leukemia

Investigating liquid cancers with Revvity technologies

Leukemia is a group of liquid tumors that target blood cells and bone marrow, with a marked predominance in Western countries. An estimated 300,000 new cases of leukemia (2.8% of all new cancer cases) are diagnosed globally each year. Of the four common types of leukemia in adults, acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL) occur most frequently. Various signaling pathways are under investigation to treat these two cancers, which are associated with a high resistance to conventional chemotherapy.

In this literature review, we focus on some of the signaling pathways and give examples of how HTRF KinEASE and AlphaLISA SureFire assays can be used in the development of novel therapies for leukemia treatment.

Featured in this note:

• Assay principle and workflow
• Consistent results (data and graphs)
• Informative materials and methods, including references

For research use only. Not for use in diagnostic procedures.